How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,041 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Effect of Antithyroid Therapies on Bone and Body Composition: A Prospective, Randomized, Clinical Study Comparing Antithyroid Drugs with Radioiodine Therapy. Full Text available with Trip Pro

Effect of Antithyroid Therapies on Bone and Body Composition: A Prospective, Randomized, Clinical Study Comparing Antithyroid Drugs with Radioiodine Therapy. Thyrotoxicosis is associated with loss of body weight and bone mineral content (BMC). Antithyroid drugs (ATD) and radioiodine therapy (RIT) are the common options for the management of thyrotoxicosis. We evaluated the effect of ATD and RIT on BMC and body composition.In this prospective study, we randomized 60 patients of thyrotoxicosis (...) before the diagnosis. A total of 51 patients had Graves' disease, and the remaining 9 had toxic multinodular goiter. BMC at lumbar spine and femoral neck improved with both the therapies similarly at the end of 1 year. The body weight, protein, and fat content also increased after 1 year of observation similar between the two groups. None of the observed parameters showed a difference with regard to the mode of ATD.ATD and RIT have comparable effects on the bone and body composition in the management

2019 Indian journal of endocrinology and metabolism Controlled trial quality: uncertain

2. Impaired quality of life after radioiodine therapy compared with antithyroid drugs or surgical treatment for Graves' hyperthyroidism. A long-term follow-up with ThyPRO and SF-36. (Abstract)

Impaired quality of life after radioiodine therapy compared with antithyroid drugs or surgical treatment for Graves' hyperthyroidism. A long-term follow-up with ThyPRO and SF-36. Hyperthyroidism is known to have a significant impact on quality of life (QoL), at least in the short term. The purpose of the present study was to assess QoL in patients 6-10 years after treatment for Graves' disease (GD) with radioiodine (RAI) compared to those treated with thyroidectomy or antithyroid drugs (ATD

2019 Thyroid

3. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. (Abstract)

Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. A relationship between iodine intake and the effectiveness of antithyroid drug (ATD) therapy for Graves' disease (GD) has been suggested, and strict restriction of iodine intake has been tried in the treatment of GD in some studies. However, it is unclear whether dietary iodine supplementation improves the prognosis of ATD therapy for GD (...) . This study aimed to clarify whether optimal iodine supplementation during antithyroid drug therapy for GD is associated with lower recurrence rates than iodine restriction.This was a prospective randomized trial of newly diagnosed patients with GD. Patients with newly diagnosed GD were recruited. After ATD therapy and strict dietary iodine restriction for 1 month, patients (n = 459) were randomly assigned to iodine-supplemented and iodine-restricted groups. After exclusion, 405 patients finally completed

2018 Clinical endocrinology Controlled trial quality: uncertain

4. Timing of shift in antithyroid drug therapy and birth defects. (Abstract)

Timing of shift in antithyroid drug therapy and birth defects. 30458113 2019 01 23 1557-9077 29 1 2019 Jan Thyroid : official journal of the American Thyroid Association Thyroid Timing of Shift in Antithyroid Drug Therapy and Birth Defects. 155-156 10.1089/thy.2018.0621 Andersen Stine Linding SL 1 Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark. 2 Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. Andersen Stig S 3 Department (...) of Geriatrics, Aalborg University Hospital, Aalborg, Denmark. 4 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. eng Journal Article 2018 12 31 United States Thyroid 9104317 1050-7256 2018 11 21 6 0 2018 11 21 6 0 2018 11 21 6 0 ppublish 30458113 10.1089/thy.2018.0621

2018 Thyroid

5. ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later Full Text available with Trip Pro

ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later The thionamide antithyroid drugs were discovered in large part following serendipitous observations by a number of investigators in the 1940s who found that sulfhydryl-containing compounds were goitrogenic in animals. This prompted Prof. Edwin B Astwood to pioneer the use of these compounds to treat hyperthyroidism in the early 1940s and to develop the more potent and less toxic drugs that are used today. Despite their simple (...) molecular structure and ease of use, many uncertainties remain, including their mechanism(s) of action, clinical role, optimal use in pregnancy and the prediction and prevention of rare but potentially life-threatening adverse reactions. In this review, we summarize the history of the development of these drugs and outline their current role in the clinical management of patients with hyperthyroidism.© 2018 European Society of Endocrinology

2018 European Journal of Endocrinology

6. Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence Full Text available with Trip Pro

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence Graves' disease (GD) is the most common cause of hyperthyroidism worldwide. Current therapeutic options for GD include antithyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients and clinicians due to some advantages including normalizing thyroid function in a short time, hardly causing hypothyroidism, and ameliorating immune disorder while avoiding radiation (...) . Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy. This paper reviewed the current knowledge of ATD treatment and mainly focused on influencing factors for recurrence in GD patients with ATD treatment.

2017 International journal of endocrinology

7. Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy

Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy Prescrire IN ENGLISH - Spotlight ''Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy '', 1 March 2017 {1} {1} {1} | | > > > Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Graves' disease in adults. Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy FEATURED REVIEW Graves' disease is the most frequent cause of hyperthyroidism. What is the best treatment for adults with Graves' disease? To answer this question, we reviewed the literature using the standard Prescrire methodology. Full review (6 pages) available for download by subscribers. Abstract What is the best treatment for adults with Graves

2017 Prescrire

8. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. Full Text available with Trip Pro

Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. Genotyping increases the accuracy of a clinical score (based on pretreatment age, goiter size, FT4, TBII) for predicting recurrence of Graves' hyperthyroidism after a course of antithyroid drugs: a prospective study.

2016 Journal of Clinical Endocrinology and Metabolism

9. AntiNeutrophil Cytoplasmic Antibody (ANCA)-positive small-vessel vasculitis associated with antithyroid drug therapy: How significant is the clinical problem? (Abstract)

AntiNeutrophil Cytoplasmic Antibody (ANCA)-positive small-vessel vasculitis associated with antithyroid drug therapy: How significant is the clinical problem? The aim of this review was to delineate the characteristics of antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis associated with antithyroid drugs (ATD). A PubMed search was made for English language articles using the search terms antithyroid drugs AND ANCA OR ANCA-associated vasculitis.The literature includes (...) approximately 260 case reports of ANCA-associated small-vessel vasculitis related to ATD, with 75% of these associated with thiouracil derivatives (propylthiouracil [PTU]) and 25% with methyl-mercapto-imidazole derivatives (MMI/TMZ). The prevalence of ANCA-positive cases caused by ATD varied between 4% and 64% with PTU (median 30%), and 0% and 16% with MMI/TMZ (median 6%). Young age and the duration of ATD therapy were the main factors contributing to the emergence of ANCA positivity. Before ATD therapy

2015 Thyroid

10. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. Full Text available with Trip Pro

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.A prospective randomized clinical trial with long-term follow-up was conducted to evaluate (...) the effects of a second course of ATD therapy.A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod

2015 European journal of endocrinology / European Federation of Endocrine Societies Controlled trial quality: uncertain

11. A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment Full Text available with Trip Pro

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD (...) for 72 months. This was an unusual case in which a serious side effect developed during a second ATD course. It is essential that clinicians remain vigilant to the fact that antithyroid drugs can induce agranulocytosis several years after initiated.

2018 Clinical Case Reports

12. Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. (Abstract)

Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study. Untreated or insufficiently treated Graves disease in pregnancy may pose risks to both mother and fetus. Antithyroid drugs (ATDs) are the treatment mainstay, but the potential teratogenic effect of these drugs has prompted clinicians to question the safe management of this vulnerable population.To examine the association between maternal prescriptions for ATDs and congenital malformations in live births.Nationwide

2018 Annals of Internal Medicine

13. Perioperative Management and Outcomes of Hyperthyroid Patients Unable to Tolerate Antithyroid Drugs. (Abstract)

Perioperative Management and Outcomes of Hyperthyroid Patients Unable to Tolerate Antithyroid Drugs. Prior to thyroidectomy for hyperthyroidism, it is recommended that patients are managed with antithyroid drugs (ATDs) and rendered euthyroid to decrease the risk of thyroid storm. However, not all patients tolerate ATD and the risk of thyroid storm during thyroidectomy in these patients is unclear. Therefore, the aim of this study was to compare the management and outcomes of hyperthyroid

2020 World Journal of Surgery

14. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Full Text available with Trip Pro

Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Antithyroid drugs (ATDs) may have teratogenic effects when used in early pregnancy.To review the association between the time period of ATD exposure in early pregnancy and the development of birth defects.We identified publications on birth defects after early pregnancy exposure to the ATDs methimazole (MMI; and its prodrug carbimazole (CMZ

2014 European Journal of Endocrinology

15. Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report Full Text available with Trip Pro

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report Graves thyrotoxicosis rarely presents with painless jaundice resulting from hyperthyroidism-associated hepatotoxicity, without preexisting liver disease. Management in patients with this presentation is challenging, given that the thionamides, methimazole and propylthiouracil, have both been associated with drug-induced liver injury. Radioactive iodine ablation and thyroidectomy are well (...) -established alternatives, but each have their associated risks and contraindications. We present an unusual case of severe hyperthyroidism-associated hepatotoxicity, in which adjuvant therapies, including glucocorticoids, saturated solution of potassium iodide, and cholestyramine, were used as a bridge to definitive therapy with thyroidectomy.

2017 Journal of the Endocrine Society

16. Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? Full Text available with Trip Pro

and cardiac function. A combination of antithyroid drug and TRIAC therapy may prevent thyrotoxic cardiomyopathy and its decompensation in homozygous or even heterozygous RTHβ in which life-threatening hyperthyroid features predominate. (...) Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure? Resistance to thyroid hormone β (RTHβ) due to homozygous THRB defects is exceptionally rare, with only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is recognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a 9-year-old boy harboring a biallelic THRB mutation (R243Q

2017 Journal of the Endocrine Society

17. Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. Full Text available with Trip Pro

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. Purpose. To study predictors of attaining (part 1) and sustaining (part 2) remission in patients with Graves' hyperthyroidism (GH) treated with antithyroid drugs (ATD). Methods. In the prospective first part, the included patients were treated with ATD until a prespecified definition of remission (thyrotropin > 0.4 mU/L and TSH-receptor antibodies (TRAb) ≤ 1. 0

2019 Journal of thyroid research Controlled trial quality: uncertain

18. Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan. (Abstract)

Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan. Background: The prevalence of antithyroid drug (ATD)-related drug-induced liver injury (DILI) has been reported to vary among patients in several countries. The purpose of this study was to summarize the prevalence of liver injury induced by ATD and to determine the actual prevalence of severe liver injury. Methods: The medical records of 18,558 patients who were newly (...) years (range 10-82 years). Nine of 461 patients had severe DILI with both drugs. The total prevalence of severe DILI in this study was 2.5%, and the prevalence of DILI by drug was 1.4% with metimazole (MMI) (n = 198) and 6.3% with propylthiouracil (PTU) (n = 272) (p < 0.001). The prevalence of the most severe ATD-related DILI was 0.22% (n = 40), and the prevalence for each drug was 0.08% with MMI (n = 11) and 0.68% with PTU (n = 29). The median time to DILI development was 30 days (range 7-314 days

2019 Thyroid

19. Maternal thyroid function, use of antithyroid drugs in early pregnancy and birth defects. (Abstract)

Maternal thyroid function, use of antithyroid drugs in early pregnancy and birth defects. Antithyroid drug (ATD) therapy in early pregnancy is associated with birth defects, but more data are needed to substantiate the risk associated with different types of ATD. Furthermore, the role of abnormal maternal thyroid function per se remains unclarified.To evaluate the risk of birth defects associated with the use of ATD in an extended nationwide cohort and the role of abnormal maternal thyroid

2019 Journal of Clinical Endocrinology and Metabolism

20. Increased Risk of Antithyroid Drugs Agranulocytosis Associated with Amiodarone-induced Thyrotoxicosis: a Population-based Cohort Study. (Abstract)

Increased Risk of Antithyroid Drugs Agranulocytosis Associated with Amiodarone-induced Thyrotoxicosis: a Population-based Cohort Study. Agranulocytosis occurs in 0.2-0.5% of patients treated with the antithyroid drugs (ATDs) methimazole and propylthiouracil. The objectives of this study were to evaluate the risk of ATD-related agranulocytosis in patients with amiodarone-induced thyrotoxicosis (AIT), and to compare it with the agranulocytosis risk in patients with thyrotoxicosis due to other

2019 Thyroid

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>